Botanix Pharmaceuticals (BOT) Q4 2026 TU earnings summary

Executive summary

• Sofdra, an FDA-approved topical gel for primary axillary hyperhidrosis, targets a large underserved US market of 10 million patients and has seen strong adoption and satisfaction among physicians and patients.

• Transitioned from development to commercial stage, with Sofdra now generating revenue in the U.S. and leveraging a scalable fulfillment platform for future product integration.

• Achieved 25% quarter-over-quarter growth in prescriptions shipped, reaching 33,358 in Q4 FY26, with June marking a record month at almost 13,000 shipments.

• Leadership team with deep dermatology experience, focusing on operational efficiencies and disciplined pursuit of value-creating opportunities.

• Strategic focus on sales force realignment, cost control, and expanding gross margins through supply chain initiatives.

Financial highlights

• Q4 FY26 net revenue for Sofdra rose 45% to $10.1 million from $6.9 million in Q3 FY26, rebounding after a seasonal Q3 dip due to U.S. insurance deductible resets.

• Gross-to-net yield improved to 22% in Q4 FY26 from 18% in Q3 FY26, with expectations for continued improvement.

• Operating cash outflow reduced by 54% to $10.6 million in Q4 FY26, driven by higher sales receipts and normalized inventory spending.

• Cash and cash equivalents at quarter-end were $36.6 million, up from $22.1 million in Q3 FY26, supported by capital raises.

• Gross sales of Sofdra reached $46.7 million in Q4 FY26, up from $38.0 million in Q3 FY26.

Outlook and guidance

• Expect continued revenue and gross-to-net growth, with cost reductions from a new API supplier projected to lower COGS by 25%-40%.

• Operating costs to decrease by 12% from sales force optimization starting July 31, 2026.

• No major API purchases expected until December 2027; near-term spend to rise temporarily due to technical transfer and manufacturing scale-up.

• The company is preparing to add new products to its platform and expand licensing opportunities, aiming to accelerate growth and profitability.

• Sales momentum for Sofdra is expected to continue, with 100% of surveyed healthcare providers planning to maintain or increase prescribing in the next six months.